Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...

In patients with chronic obstructive pulmonary disease (COPD), increasing frequency and severity of exacerbations were linked to a higher risk of future exacerbations and all-cause and COPD-related ...

After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...

bronchodilators, COPD Triple therapy with budesonide/glycopyrrolate/formoterol fumarate in patients with COPD, regardless of exacerbation history, reduced ...

Woman suffering an anxiety attack alone in the night How does a delay in initiating triple therapy affect patients with COPD with a history of several moderate COPD exacerbations during a 1-year ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

New research shows that individual exacerbations in chronic obstructive lung disease (COPD) themselves increase the likelihood of repeat exacerbations, even after five days of full, asymptomatic ...

Evidence suggests higher levels of iron in pulmonary macrophages heightens the risk of infectious exacerbations. A new report yielded fresh insights into the role of pulmonary iron in chronic ...

Poor quality of sleep was found to have a strong association with symptomatic exacerbations of chronic obstructive pulmonary disease, according to a recent Canadian study presented at the 2016 ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...